Targeting of intracellular oncoproteins with peptide-centric CARs

The majority of oncogenic drivers are intracellular proteins, constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes(1). However, most cancers have a modest mutational burden that is insufficient for generating...

Descripción completa

Detalles Bibliográficos
Autores principales: Yarmarkovich, Mark, Marshall, Quinlen F., Warrington, John M., Premaratne, Rasika, Farrel, Alvin, Groff, David, Li, Wei, di Marco, Moreno, Runbeck, Erin, Truong, Hau, Toor, Jugmohit S., Tripathi, Sarvind, Nguyen, Son, Shen, Helena, Noel, Tiffany, Church, Nicole L., Weiner, Amber, Kendsersky, Nathan, Martinez, Dan, Weisberg, Rebecca, Christie, Molly, Eisenlohr, Laurence, Bosse, Kristopher R., Dimitrov, Dimiter S., Stevanovic, Stefan, Sgourakis, Nikolaos G., Kiefel, Ben R., Maris, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665195/
https://www.ncbi.nlm.nih.gov/pubmed/37938771
http://dx.doi.org/10.1038/s41586-023-06706-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665195/
https://www.ncbi.nlm.nih.gov/pubmed/37938771
http://dx.doi.org/10.1038/s41586-023-06706-0

Ejemplares similares